$ALLO

DelveInsight forecasts the CAR T-cell therapy market for non-Hodgkin lymphoma will grow at about 7% CAGR through 2036, driven by rising relapsed/refractory incidence and broader clinical adoption. It cites pipeline and trial activity for products including Miltenyi’s Zamtocabtagene, Novartis’ Rapcabtagene, Allogene’s Cemacabtagene, and others. Recent updates include FDA approvals for TECARTUS and label changes for YESCARTA, plus early LB2501 results from Legend Biotech.

Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. allo-20260618 0001737287 FALSE 0001737287 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM 8-K ____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of

NULL

Allogene Therapeutics (ALLO) stock slumped by 16.01% after announcing a $175M underwritten public offering of 87.5 million shares at $2.00 per share, significantly diluting existing shareholders. The offering, designed to fund clinical trials and R&D for its CAR-T pipeline, led to an 18% intraday price drop on increased volume. Traders are closely monitoring ALLO due to the dilution, insider selling intentions, and its high-burn, high-volatility biotech profile.

Allogene Therapeutics, Inc. announced it will host a conference call and webcast on Monday, April 13, 2026, to review interim futility analysis data from its pivotal Phase 2 ALPHA3 trial. This trial evaluates cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL). The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.

This article lists 12 healthcare stocks that experienced significant movement in Friday's after-market trading session. Gainers include Virax Biolabs Group (VRAX), IDEAYA Biosciences (IDYA), Allogene Therapeutics (ALLO), Oncolytics Biotech (ONCY), PureTech Health (PRTC), and PharmaCyte Biotech (PMCB). Losers include Wellgistics Health (WGRX), Nasus Pharma (NSRX), Vivos Therapeutics (VVOS), Estrella Immunopharma (ESLA), Geovax Labs (GOVX), and Profusa (PFSA), with specific percentage changes and market caps provided for each.

Allogene Therapeutics is experiencing a surge in stock value due to a positive shift in the biotechnology sector, driven by strategic acquisitions and licensing deals. The cell therapy specialist's clinical pipeline is attracting institutional investors, pushing its stock close to its yearly peak with an approximately 96% gain since the start of the year. Future growth hinges on concrete data readouts from its research pipeline and further industry consolidation.

Allogene Therapeutics is making strides in CAR T therapy, aiming to revolutionize patient care through innovative cell therapy developments. The company is focused on improving access to advanced treatments and holds promise for patients with severe autoimmune diseases. This includes the introduction of ALLO-329, a next-generation CAR-T therapy utilizing its Dagger technology platform.

Allogene Therapeutics CEO David Chang sold 47,763 shares of the company's stock on March 16th, reducing his stake by 0.92%. The transaction, valued at over $117,000, leaves him with approximately 5.15 million shares. Despite the insider selling, analysts maintain a "Moderate Buy" rating for ALLO with an average price target of $8.50, and the company recently beat EPS estimates.

Allogene Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighting a net loss of $190.9 million or $0.87 per share for the year. The company provided updates on key pipeline milestones, including an interim futility analysis for the ALPHA3 trial of cema-cel in April 2026 and proof-of-concept data for the RESOLUTION trial of ALLO-329 in autoimmune disease in June 2026. Allogene ended 2025 with $258.3 million in cash, cash equivalents, and investments, extending its cash runway into the first quarter of 2028.